ABSTRACT
A new technique for the treatment of diplopia secondary to cosmetic botulinum toxin A use is described. In this interventional case reports, two consecutive patients who developed diplopia after periocular cosmetic use of botulinum toxin A were treated with intramuscular botulinum toxin A injection into the antagonist extraocular muscle. Diplopia resolved in both patients in less than 1 week with no side effects or complications. In conclusion, the injection of intramuscular botulinum toxin A is an encouraging option for treatment of diplopia secondary to botulinum toxin A use for facial lifting.
Subject(s)
Botulinum Toxins, Type A/therapeutic use , Diplopia/drug therapy , Neuromuscular Agents/therapeutic use , Adult , Botulinum Toxins, Type A/adverse effects , Diplopia/chemically induced , Female , Humans , Injections, Intramuscular/methods , Middle Aged , Neuromuscular Agents/adverse effects , Oculomotor Muscles , Treatment OutcomeABSTRACT
A new technique for the treatment of diplopia secondary to cosmetic botulinum toxin A use is described. In this interventional case reports, two consecutive patients who developed diplopia after periocular cosmetic use of botulinum toxin A were treated with intramuscular botulinum toxin A injection into the antagonist extraocular muscle. Diplopia resolved in both patients in less than 1 week with no side effects or complications. In conclusion, the injection of intramuscular botulinum toxin A is an encouraging option for treatment of diplopia secondary to botulinum toxin A use for facial lifting.
Uma nova técnica para tratamento de diplopia secundária ao uso estético da toxina botulínica A é descrito. Nestes relatos de casos, dois pacientes consecutivos que desenvolveram diplopia após uso cosmético de toxina botulínica A periocular foram tratados com injeção de toxina botulínica A no músculo extraocular antagonista. A diplopia melhorou em menos de uma semana nos dois pacientes, sem efeitos colaterais. Consideramos o uso de injeção intramuscular de toxina botulínica A como uma possível opção para o tratamento da diplopia secundária ao uso da toxina botulínica A para rejuvenescimento facial.
